|
A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N+I) or nivolumab plus chemotherapy (N+CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648. |
|
|
Honoraria - Bristol-Myers Squibb; Eisai; Lilly; Novartis; Roche/Genentech; SERVIER |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics |
Research Funding - Janssen-Cilag (Inst); Lilly (Inst) |
Travel, Accommodations, Expenses - BMS; SERVIER |
|
|
Honoraria - Incyte; SERVIER |
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER; Taiho Oncology |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene |
Research Funding - Amgen; Incyte (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER |
|
|
No Relationships to Disclose |
|
|
Employment - Adelphi; Phastar |
Stock and Other Ownership Interests - AstraZeneca |
|
|
Employment - Bristol Myers Squibb |
Stock and Other Ownership Interests - Bristol Myers Squibb; GlaxoSmithKline |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb/Celgene |
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene |